News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Promising Prognostic and Preclinical Data for Acute Myeloid Leukemia and BerGenBio AS’s BGB324 at American Society of Hematology



12/7/2011 6:25:37 AM

BERGEN, Norway--(BUSINESS WIRE)--BerGenBio AS, an emerging oncology biopharma, is developing a first in class inhibitor of Axl kinase, BGB324. Promising preclinical data on the importance of Axl kinase in Acute Myeloid Leukemia (AML) will be presented at the 53rd American Society of Hematology Annual Meeting and Exposition, in San Diego. The research, completed by Sonja Loges, M.D., Ph.D. from University of Hamburg, suggests that Axl is a useful prognostic indictor for AML and that BerGenBio`s inhibitor, BGB324, is a highly effective therapeutic candidate.

Read at BioSpace.com

Related News

comments powered by Disqus
   
Leukemia

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES